2025
Medications for opioid use disorder shape immune responses during chronic HIV infection
Collora J, Steinhauser S, Davenport T, Lin D, Eshetu A, Zeidi S, Kim R, Frank C, Kluger Y, Springer S, Ho Y. Medications for opioid use disorder shape immune responses during chronic HIV infection. Cell Reports Medicine 2025, 6: 102159. PMID: 40460829, PMCID: PMC12208330, DOI: 10.1016/j.xcrm.2025.102159.Peer-Reviewed Original ResearchConceptsOpioid use disorderTumor necrosis factorImmune responseHIV infectionAssociated with HIV replicationCytotoxic T cell populationsRisk of opioid use disorderUse disorderPeripheral blood immune cellsI interferonChronic HIV infectionRNA expressionPartial agonist buprenorphineT cell populationsShape immune responsesBlood immune cellsType I interferonImprove immune responsesAgonist buprenorphineAgonist methadoneHIV expressionAntagonist naltrexoneHIV replicationImmune profileImmune cells
2023
HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal
Pierce C, Loh L, Steach H, Cheshenko N, Preston-Hurlburt P, Zhang F, Stransky S, Kravets L, Sidoli S, Philbrick W, Nassar M, Krishnaswamy S, Herold K, Herold B. HSV-2 triggers upregulation of MALAT1 in CD4+ T cells and promotes HIV latency reversal. Journal Of Clinical Investigation 2023, 133: e164317. PMID: 37079384, PMCID: PMC10232005, DOI: 10.1172/jci164317.Peer-Reviewed Original ResearchConceptsHIV-1 reactivationHIV latency reversalT cellsLatency reversalHuman CD4HIV-1 viral loadHIV-1 restriction factorsHSV-2 recurrencesHSV-2 infectionHIV-1 latencyUpregulation of MALAT1Primary human CD4HSV-2 proteinsViral loadHIV replicationPeripheral bloodMALAT1 expressionHSV-2Tissue reservoirsCD4Viral replicationExpression of transcriptsBystander cellsRestriction factorsMALAT1
2019
Treatment of Central Nervous System Manifestations of HIV in the Current Era
Handoko R, Spudich S. Treatment of Central Nervous System Manifestations of HIV in the Current Era. Seminars In Neurology 2019, 39: 391-398. PMID: 31378874, DOI: 10.1055/s-0039-1688915.Peer-Reviewed Original ResearchConceptsCSF HIVTreatment intensificationCentral nervous system opportunistic infectionsHuman immunodeficiency virus (HIV) infectionCentral nervous system manifestationsCurrent ARV regimenHIV resistance mutationsNeuropsychiatric adverse effectsImmunodeficiency virus infectionNervous system manifestationsNeuropsychiatric side effectsMagnetic resonance imagingCerebrospinal fluid dataSystemic HIVHigh CNS penetrationARV regimenSystem manifestationsOpportunistic infectionsHIV replicationTreatment switchLumbar punctureSleep disturbancesVirus infectionCCR5 inhibitorsNeuropsychiatric impairment
2018
Brief Report
Yanik EL, Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Horberg MA, Moore RD, Mathews WC, Justice AC, Hessol NA, Mayor AM, Gill MJ, Brooks JT, Sun J, Althoff KN, Engels EA, Silverberg MJ, Dubrow R. Brief Report. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 499-504. PMID: 29771785, PMCID: PMC6037538, DOI: 10.1097/qai.0000000000001719.Peer-Reviewed Original ResearchConceptsMelanoma incidenceAntiretroviral therapyGeneral populationMelanoma riskNorth American AIDS Cohort CollaborationRelationship of immunosuppressionWhite general populationHIV RNA levelsStandardized incidence ratiosCutaneous melanoma incidenceUltraviolet B exposureHigher melanoma incidenceHigh UVB exposureCohort CollaborationSkin surveillanceCD4 countHIV RNAImmune dysfunctionIncidence ratiosCox regressionHIV replicationRisk factorsCalendar periodWhite raceClinical care
2016
CROI 2016: Neurologic Complications of HIV Infection.
Spudich SS, Ances BM. CROI 2016: Neurologic Complications of HIV Infection. Topics In Antiviral Medicine 2016, 24: 29-37. PMID: 27398860, PMCID: PMC6148921.Peer-Reviewed Original ResearchConceptsCentral nervous systemHIV infectionTraditional vascular risk factorsPrognosis of handSuppressive antiretroviral treatmentVascular risk factorsStandard antiretroviral therapyPotential adjunctive therapyLarge epidemiologic studiesMacrophage lineage cellsRecreational drug useHIV escapeHIV measuresAntiretroviral therapyHepatic dysfunctionNeurologic complicationsAdjunctive therapyAntiretroviral treatmentSystemic compartmentOpportunistic infectionsHIV replicationFemale sexPotential complicationsRisk factorsNeurocognitive disorders
2015
Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers
Walker WE, Kurscheid S, Joshi S, Lopez CA, Goh G, Choi M, Barakat L, Francis J, Fisher A, Kozal M, Zapata H, Shaw A, Lifton R, Sutton RE, Fikrig E. Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers. Journal Of Virology 2015, 89: 5502-5514. PMID: 25740989, PMCID: PMC4442529, DOI: 10.1128/jvi.00118-15.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCase-Control StudiesCD4-Positive T-LymphocytesChemokine CCL3Chemokine CCL4Chemokine CCL5Chemokines, CCCohort StudiesFemaleGene DosageHIV InfectionsHIV Long-Term SurvivorsHIV-1Host-Pathogen InteractionsHumansMacrophage Inflammatory ProteinsMaleMiddle AgedReceptors, CCR5Receptors, CXCR4RNA, MessengerUp-RegulationConceptsElite controllersHIV-seropositive individualsAntiretroviral therapyT cellsMIP-1βMIP-1αHIV infectionSeropositive individualsAbsence of ARTR5-tropic HIV-1Macrophage inflammatory protein-1αR5-tropic HIVInflammatory protein-1αT cell resistancePandemic health problemRANTES chemokinesHIV replicationRare patientsHealthy controlsTherapeutic effectHIV entryHIV-1X4-tropicHealth problemsProtein-1αNeuropathogenesis of HIV: From Initial Neuroinvasion to HIV-Associated Neurocognitive Disorder (HAND)
Zayyad Z, Spudich S. Neuropathogenesis of HIV: From Initial Neuroinvasion to HIV-Associated Neurocognitive Disorder (HAND). Current HIV/AIDS Reports 2015, 12: 16-24. PMID: 25604237, PMCID: PMC4741099, DOI: 10.1007/s11904-014-0255-3.Peer-Reviewed Original ResearchConceptsHIV-Associated Neurocognitive DisordersCentral nervous systemCombination antiretroviral therapyNeurocognitive disordersTissue reservoirsInitial viral entryTargets of infectionCourse of infectionEarly-stage infectionHIV eradicationAntiretroviral therapyHIV neuropathogenesisSevere immunosuppressionClinical symptomsHIV replicationHIV epidemicLocal infectionCNS cellsPathological involvementPathogenetic processSevere formNervous systemNeurological diseasesAdvanced stageHIV
2014
CROI 2014: Neurologic complications of HIV infection.
Spudich SS. CROI 2014: Neurologic complications of HIV infection. Topics In Antiviral Medicine 2014, 22: 594-601. PMID: 24901885, PMCID: PMC6148910.Peer-Reviewed Original ResearchConceptsCentral nervous systemCerebrospinal fluidHIV infectionCNS immune activationEarly HIV diagnosisHost genetic determinantsNeurologic complicationsNeurologic morbidityHIV diagnosisOpportunistic infectionsPersistent abnormalitiesHIV replicationImmune activationCNS dysfunctionCSF biomarkersNeurocognitive disordersHIV detectionNervous systemCognitive impairmentHIVSalutary effectsMild formEnd pointInfectionPotential mediators
2013
Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase
Iyidogan P, Sullivan T, Chordia M, Frey K, Anderson K. Design, Synthesis, and Antiviral Evaluation of Chimeric Inhibitors of HIV Reverse Transcriptase. ACS Medicinal Chemistry Letters 2013, 4: 1183-1188. PMID: 24900627, PMCID: PMC4027223, DOI: 10.1021/ml4002979.Peer-Reviewed Original ResearchH-phosphonatesLow nanomolar antiviral potencyReduced HIV replicationInhibitors of HIV reverse transcriptasePolymethylene linkerHIV replicationTMC derivativesAnti-HIV AgentsAntiviral evaluationAntiviral activity profileChimeric inhibitorsHIV reverse transcriptaseCell-based assaysAntiviral potencyReverse transcriptaseIC50 valuesCellular levelNucleosideInhibitorsThymidinePolymethylene
2008
Effective suppression of HIV-1 by artificial bispecific miRNA targeting conserved sequences with tolerance for wobble base-pairing
Son J, Uchil PD, Kim YB, Shankar P, Kumar P, Lee SK. Effective suppression of HIV-1 by artificial bispecific miRNA targeting conserved sequences with tolerance for wobble base-pairing. Biochemical And Biophysical Research Communications 2008, 374: 214-218. PMID: 18619945, DOI: 10.1016/j.bbrc.2008.06.125.Peer-Reviewed Original ResearchConceptsFunctional RNAiHIV-1 isolatesHigh genetic diversityAntiviral therapyHIV replicationHIV-1Vif sequencesArtificial microRNAsGenetic diversityGenome sequenceSustained inhibitionVif geneHIV sequencesVariant residuesSequence databasesLuciferase constructSimultaneous targetingNatural variantsViral sequencesRNAiSequenceInhibition
2005
Endothelial Cells Promote Human Immunodeficiency Virus Replication in Nondividing Memory T Cells via Nef-, Vpr-, and T-Cell Receptor-Dependent Activation of NFAT
Choi J, Walker J, Talbert-Slagle K, Wright P, Pober JS, Alexander L. Endothelial Cells Promote Human Immunodeficiency Virus Replication in Nondividing Memory T Cells via Nef-, Vpr-, and T-Cell Receptor-Dependent Activation of NFAT. Journal Of Virology 2005, 79: 11194-11204. PMID: 16103171, PMCID: PMC1193601, DOI: 10.1128/jvi.79.17.11194-11204.2005.Peer-Reviewed Original ResearchConceptsMemory T cellsHuman immunodeficiency virus (HIV) replicationImmunodeficiency virus replicationT cellsViral replicationEndothelial cellsAntiretroviral therapyHIV replicationSuboptimal T cell receptor (TCR) stimulationHIV Type 1 ReplicationVirus replicationMajor histocompatibility complex (MHC) class II moleculesType 1 replicationTumor necrosis factorMHC class IIClass II moleculesT cell receptor stimulationVirus-producing cellsReceptor-dependent activationNef-dependent mannerEffector cytokinesHuman endothelial cellsHLA-DRIL-6Presence of EC
2004
Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. The Lancet 2004, 364: 51-62. PMID: 15234856, DOI: 10.1016/s0140-6736(04)16589-6.Peer-Reviewed Original ResearchConceptsProportional hazards modelVirological failureCD4 cell count slopesHIV-1 RNA concentrationsCox proportional hazards modelCD4 cell countPredictors of deathAntiretroviral therapyHIV cohortDual therapyClinical outcomesViral loadHIV replicationDrug classesTreatment strategiesTreatment informationPatientsDemographic characteristicsRNA concentrationRegression analysisTherapyFailureCohort
2001
Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug
KRYNETSKAIA N, FENG J, KRYNETSKI E, GARCIA J, PANETTA J, ANDERSON K, EVANS W. Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. The FASEB Journal 2001, 15: 1902-1908. PMID: 11532970, DOI: 10.1096/fj.01-0124com.Peer-Reviewed Original ResearchConceptsAnti-retroviral agentsHIV replicationHIV-1 reverse transcriptaseReverse transcriptaseTreatment of HIVHuman lymphocyte culturesDifferent medicationsHost lymphocytesAdditive cytotoxicityHIV-1Old drugsLymphocyte culturesActive metaboliteHuman lymphocytesMinimal toxicityLymphocytesThioguanineSubstantial inhibitionTreatmentInhibitionHIV proteaseEarly stagesMedicationsHIVPatients
1998
Vitamin A Supplementation and Human Immunodeficiency Virus Load in Injection Drug Users
Semba R, Lyles C, Margolick J, Caiaffa W, Farzadegan H, Cohn S, Vlahov D. Vitamin A Supplementation and Human Immunodeficiency Virus Load in Injection Drug Users. The Journal Of Infectious Diseases 1998, 177: 611-616. PMID: 9498439, DOI: 10.1086/514235.Peer-Reviewed Original ResearchConceptsCD4 lymphocyte countHigh-dose vitaminHIV loadInjection drug usersLymphocyte countDrug usersVitamin AHuman immunodeficiency virus (HIV) infectionPlacebo-controlled clinical trialHuman immunodeficiency virus loadImmunodeficiency virus infectionUse of vitaminsPlasma vitaminHIV replicationVirus loadClinical trialsVirus infectionClinical investigationRetinol equivalentsSupplementationRetinoic acid response elementVitaminWeeksAcid response elementCount
1996
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation.
Goletti D, Weissman D, Jackson R, Graham N, Vlahov D, Klein R, Munsiff S, Ortona L, Cauda R, Fauci A. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. The Journal Of Immunology 1996, 157: 1271-8. PMID: 8757635, DOI: 10.4049/jimmunol.157.3.1271.Peer-Reviewed Original ResearchConceptsHIV replicationMTB diseaseMycobacterium tuberculosisLymph node mononuclear cellsViral replicationCellular activationProtein derivative positivityPlasma viral loadAg-specific activationT cell-depleted lymphocytesPPD-negative donorsHIV diseaseHIV infectionAcute phaseViral loadImmune activationMononuclear cellsPPD positivityHealthy donorsHIV epidemicT cellsPrimary PBMCsHIV infection modelEpidemiology dataHIV
1995
Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease.
Bukrinsky M, Nottet H, Schmidtmayerova H, Dubrovsky L, Flanagan C, Mullins M, Lipton S, Gendelman H. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. Journal Of Experimental Medicine 1995, 181: 735-745. PMID: 7530762, PMCID: PMC2191885, DOI: 10.1084/jem.181.2.735.Peer-Reviewed Original ResearchConceptsEffector cell functionInducible NO synthaseBrain tissueAIDS patientsHIV-1Human immunodeficiency virus (HIV) persistenceHuman immunodeficiency virus type 1Human monocytesNitric oxide synthase activityImmunodeficiency virus type 1HIV-macrophage interactionsPediatric AIDS patientsHIV-1 diseaseCell functionHIV-1 infectionMacrophage antigen presentationExpression of NOSOxide synthase activityVirus-infected macrophagesPostmortem brain tissueVirus type 1Productive viral replicationCultured human monocytesHIV encephalitisHIV replication
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply